Amylyx secured a reported $500 million ahead of its regulatory submission following a buoyed readout, according to a biopharma finance report. The update frames the funding timing as closely tied to upcoming milestone moments for the company’s development path. In parallel, the same finance roundup notes Ambros is lining up a $150 million PIPE as it heads to NASDAQ via a reverse merger, suggesting capital markets continue to reward late-stage clinical catalysts and liquidity planning. For investors and pipeline planners, these moves reflect the broader sector playbook: underwriting risk after clinical signals, then preparing for submissions and potential launch readiness with near-term cash runway.